CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss ...

CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss ...

Net loss widened to $111.4 million from $106.4 million; CTX310 and zugo-cel data presentations are scheduled for November 9 and 8, 2026.

CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third ...

Fulcrum is Pairwise's proprietary CRISPR toolbox, bringing together multiple editing technologies under a single license for precise crop improvement. Founded in 1976, Kaveri has five decades of ...

Advancing oncology research Seek Labs is exploring how SAT can be applied in oncology, building on the company’s broader work in infectious disease. The Foundation’s support will advance research into ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving -1.21% from the previous trading session. The stock's change was equal to S&P 500. Elsewhere, the Dow gained 0.02%, ...

Financial markets slumped on Friday as investors bailed on technology stocks amid concerns that companies exposed to artificial intelligence are starting to wobble. The tech-heavy Nasdaq Composite ...